Gravie tightens access to GLP-1 medication

Gravie members receiving coverage for GLP-1 medication, used to treat type 2 diabetes and prescribed for weight loss, will be subject to new requirements effective July 15, 2025.

The drug’s eligibility criteria starting July 15 will require prior authorization and submission of relevant labs and provider chart notes confirming the member has type 2 diabetes. Without this step, the drug will not be covered by the prescription drug plan.

Additionally, the drug will be classed as a Tier 2 medication, known as a Preferred Brand Drug, and have a higher copay.

Any existing members using a GLP-1 medication without a confirmed diabetes diagnosis on file with Gravie’s pharmacy benefit manager, CVS Caremark, should work with their physician prior to July 15 to request a new prior authorization and confirmation of the drug’s necessity to treat type 2 diabetes. CVS Caremark will notify impacted members by mail.

Contact your Bukaty benefits consultant for additional information.